Canakinumab efficacy in refractory adult-onset PFAPA syndrome

Int J Rheum Dis. 2017 Aug;20(8):1050-1051. doi: 10.1111/1756-185X.12722. Epub 2015 Jul 22.

Authors

Giuseppe Lopalco¹, Donato Rigante², Antonio Vitale³, Francesco Caso³, Florenzo Iannone¹, Luca Cantarini³

Affiliations

¹ Rheumatology Unit, Interdisciplinary Department of Medicine, Policlinico of Bari, Bari, Italy.
² Institute of Pediatrics, Università Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.
³ Rheumatology Unit, Research Center of Systemic Autoinflammatory Diseases, and Behcet's Disease, Policlinico "Le Scotte", University of Siena, Siena, Italy.

PMID: 26200174
DOI: 10.1111/1756-185X.12722

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Age of Onset
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Fever / diagnosis
Fever / drug therapy*
Fever / immunology
Hereditary Autoinflammatory Diseases / diagnosis
Hereditary Autoinflammatory Diseases / drug therapy*
Hereditary Autoinflammatory Diseases / immunology
Humans
Lymphadenitis / diagnosis
Lymphadenitis / drug therapy*
Lymphadenitis / immunology
Male
Pharyngitis / diagnosis
Pharyngitis / drug therapy*
Pharyngitis / immunology
Stomatitis, Aphthous / diagnosis
Stomatitis, Aphthous / drug therapy*
Stomatitis, Aphthous / immunology
Syndrome
Treatment Outcome

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
canakinumab